TP53 and cancer: Finally, about 80% of ACT survivors carrying classic LFS TP53 variants develop a secondary cancer within 30 years from the diagnosis of ACT [32], whereas ACT survivors carrying the R337H variant rarely develop secondary cancers during the first four decades of life [10].